Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
January 06, 2020 06:55 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
December 17, 2019 06:55 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Interpace to Present Data at the ATA Annual Meeting
October 29, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th...
Interpace to Present at the American College of Gastroenterology Conference
October 24, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Interpace hosts 2nd Annual Fellow Programs PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its...
Interpace Diagnostics Announces Contract with Blue Cross Blue Shield of Michigan
July 31, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
In Network Access for More Than 6 Million Members PARSIPPANY, NJ, July 31, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has contracted with Blue...
Interpace Announces New Agreement with SelectHealth
July 22, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Expected to Benefit More than 850,000 Members PARSIPPANY, NJ, July 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has reached an agreement...
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
July 18, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics...
Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
July 15, 2019 16:10 ET
|
Interpace Diagnostics Group, Inc.
Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the...
Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross
June 20, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by...
Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
May 01, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Data from Registry Study Confirms the Value of ThyGenX® and ThyraMIR® in a Clinical Setting PARSIPPANY, NJ, May 01, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc....